FDA Accepts sNDA for Photodynamic Therapy in Superficial Basal Cell CarcinomaByJonah FeldmanFebruary 12th 2026
Adjuvant Cemiplimab for High-Risk CSCC: Risk Stratification in PracticeByVishal A. Patel, MDOctober 28th 2025
Evolving Treatment Strategies With Cemiplimab: Optimization and PersonalizationByVishal A. Patel, MDOctober 26th 2025